Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
about
Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and DifferencesMuscle wasting in animal models of severe illnessMuscle plasticity and β₂-adrenergic receptors: adaptive responses of β₂-adrenergic receptor expression to muscle hypertrophy and atrophyAnabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscleExpression profiling of skeletal muscle following acute and chronic beta2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm.Animal models of anorexia and cachexia.Optimal management of cancer anorexia-cachexia syndrome.Enhancement of catecholamine release from PC12 cells by the traditional Japanese medicine, rikkunshito.Cancer cachexia, mechanism and treatmentSirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?C26 cancer-induced muscle wasting is IKKβ-dependent and NF-kappaB-independent.Cancer cachexia update in head and neck cancer: Pathophysiology and treatment.Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles.Skeletal muscle atrophy is attenuated in tumor-bearing mice under chemotherapy by treatment with fish oil and selenium.The role of insulin resistance in the development of muscle wasting during cancer cachexia.Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regenerationMurine models of atrophy, cachexia, and sarcopenia in skeletal muscle.Emerging drugs for cancer cachexia.Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting.Fatigue in palliative care patients -- an EAPC approach.Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome.Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.Concurrent muscle and bone deterioration in a murine model of cancer cachexia.Update on emerging drugs for cancer cachexia.Animal models of the cancer anorexia-cachexia syndrome.Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options.Cancer-induced muscle wasting: latest findings in prevention and treatment.Skeletal muscle regeneration in cancer cachexia.Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice.A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.Theophylline is able to partially revert cachexia in tumour-bearing rats.Formoterol fumarate inhalation solution (Perforomist) for COPD.Effects of formoterol on protein metabolism in myotubes during hyperthermia.Formoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis.Phenotypic and metabolic features of mouse diaphragm and gastrocnemius muscles in chronic lung carcinogenesis: influence of underlying emphysema.Formoterol in the treatment of experimental cancer cachexia: effects on heart functionFormoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity.
P2860
Q26767412-790788E2-7BD1-40DC-94C7-4F050045343FQ27000450-EB50431E-A854-4049-A60F-032D1C710112Q27016049-9CFF1D97-AC6F-44DE-B21E-C5DC736A8E6AQ28566103-C599C526-3190-438E-BFC0-36B6E7C72C6AQ30157109-B3486858-AD45-4F22-8B06-D33224C28B6DQ30434298-E22BD5C2-BC29-4BC7-B430-6BA83F021F1CQ34417908-A9DACBBA-223A-4D6A-B249-899F1048AE25Q34468971-57E4E7BF-9EB7-4970-96BD-406DF8E5F07CQ34669440-8B960789-AC44-437B-A793-54FF7DDA5116Q34716943-FCE4C631-164F-4C78-84C1-E3EBA46E35F1Q35086723-4506CF3F-6180-4107-92A2-657849BDFDE5Q35122201-D43BF949-3253-4CC0-978A-AFEFAE86C3B7Q35545362-50018291-3A29-4576-BB5C-A87AC8F9DCA5Q35545370-5009A592-E4B1-4BC3-93B2-7CB747362328Q35689555-D21EF707-86E2-466D-8E41-E490CF191D2BQ35781409-941CFB2F-654F-42BC-9ECA-A855920DD47AQ35828084-3B2B0499-7A73-4F05-AF01-C30657A92E0AQ36028202-3D73D26E-06BC-4FDC-AE4A-0149336B9BC6Q36114861-B0435ABB-AC1B-43CA-87FE-DDBD4FC166B8Q36941459-0CEEA7FE-55EB-47C6-A185-C14DD4682E6BQ36989913-D29FA4B9-D12F-457F-AA5A-473FF6177805Q37019253-69E324EB-37E7-481C-A613-527B98F95BADQ37063833-3B6C7954-6F6C-4E3E-B92A-87A0BC8EBC85Q37103603-D07380EC-DB69-4E99-811A-36BFF5650E7EQ37129351-8FC24183-B992-4035-81B8-CBA0B930547AQ37411070-0CECF2B4-DC68-40DE-9534-86201D0E2579Q37622253-58676821-5EE1-420A-8D9D-6ECE785DD95EQ37780478-F7C02EEF-29F0-4F0B-BADD-659C6F498B38Q38290238-C64BDC2C-F168-4208-B835-5BF379BED696Q38681113-3EFE1D2B-A4B3-42FA-94CA-A543353A4DB8Q38726702-A00F59B8-AD30-4108-98AF-E4936EF03476Q39093151-A44E13D1-0E03-43BD-BF9A-B42DAC717F7FQ39218137-8F5B0FEA-CBF9-4023-BE40-F201D5CDB509Q39293834-2D7F8242-AA6A-4233-8D9E-185697069F8EQ39317855-2A3683A4-4B68-4C05-B1F7-699989668514Q39604824-406FD8B5-178F-48E8-A639-6F0CDE683F64Q39721900-0FF528B6-1CFC-4B8D-89B3-3677B2B98B6BQ41407774-7EA5005A-790F-417D-B423-5C9D768AEAC1Q42062172-33330823-DC01-4EFF-AED3-C63370320BA0Q42132692-236FF9E1-1CE8-4200-A431-C307E24600BE
P2860
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@ast
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@en
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@nl
type
label
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@ast
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@en
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@nl
prefLabel
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@ast
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@en
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
@nl
P2093
P50
P1433
P1476
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting
@en
P2093
Francisco J López-Soriano
Gemma Fuster
Maria T Figueras
Rodrigo Moore-Carrasco
Vanessa Almendro
P304
P356
10.1158/0008-5472.CAN-04-0425
P407
P577
2004-09-01T00:00:00Z